Lupin unveils generic equivalent of Revatio for Oral Suspension in US

The medication is used to treat erectile dysfunction and pulmonary arterial hypertension.

Published On 2022-09-30 10:00 GMT   |   Update On 2023-10-17 12:13 GMT
Advertisement

Mumbai: Global pharma major, Lupin Limited, has announced the launch of Sildenafil for Oral Suspension, 10 mg/mL, having received approval from the United States Food and Drug Administration (USFDA).

Sildenafil for Oral Suspension, 10 mg/mL, is a generic equivalent of Revatio for Oral Suspension, 10 mg/mL of Viatris Specialty LLC.

The medication is used to treat erectile dysfunction and pulmonary arterial hypertension.

Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of USD 64 million in the U.S. (IQVIA MAT July 2022).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas.

Read also: Lupin bags USFDA nod for Diclofenac Sodium Topical Solution to treat arthritic knee pain

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News